Please login to the form below
Tyverb
This page shows the latest Tyverb news and features for those working in and with pharma, biotech and healthcare.
Pfizer’s first-in-class breast cancer therapy wins EU licence
A number of metastatic breast cancer treatments have been rejected by the UK cost-effectiveness watchdog over the last few years, including GlaxoSmithKline's Tyverb (lapatinib) and Roche's Herceptin (trastuzumab),
Latest news
-
Oncology directions
For advanced breast cancer, Novartis's newly acquired breast cancer drug Tyverb (lapatinib) scores five, but there are four drugs that score three or less, including Eisai's breast cancer medicine
-
Novartis and GSK complete oncology and vaccines swap
Details of the asset swap were first revealed last April. Novartis claims ownership of several marketed products - including kidney cancer therapy Votrient (pazopanib) and Tyverb (lapatinib) for breast cancer - and also
-
England's Cancer Drugs Fund: Fixing a broken system
eribulin), GSK's Tyverb (lapatinib) and Novartis' Afinitor (everolimus)), were to be de-listed. ... GlaxoSmithKline's Tyverb (lapatinib):. treatment of advanced breast cancer. GlaxoSmithKline's Arzerra (ofatumumab):.
-
Pharma condemns Cancer Drugs Fund cuts
GSK. Arzerra (ofatumumab). Chronic lymphocytic leukaemia. Tyverb (lapatinib). Breast cancer. Votrient (pazopanib).
-
NHS names drugs to be re-evaluated for Cancer Drugs Fund
Chronic lymphocytic leukaemia. GlaxoSmithKline. Arzerra (ofatumumab) . Chronic lymphocytic leukaemia. Tyverb (lapatinib).
More from news
Approximately 3 fully matching, plus 26 partially matching documents found.
Latest appointments
-
GSK's oncology president joins NuCana board
During this time he has worked on major cancer products, such as Tykerb/Tyverb and Mekinist.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- How will the events and exhibitions industry change post-Coronavirus?
- Send Us a Message
- Lilly’s Verzenio scores a win in early-stage breast cancer
- Keytruda doubles five-year survival rate in NSCLC
- Researchers call on Pfizer to delay COVID-19 vaccine application
- Novavax starts first phase 3 COVID-19 vaccine trial in the UK
- Covid-19 redefines rules of customer engagement
- Ongoing Virtual Communication between MSLs and Physicians: a Customer Story
- Aurora extends exclusive collaboration with Patient Intelligence Panel (PIP Health)
- Moderna’s COVID-19 vaccine generates strong immune response in older adults
- Regeneron’s COVID-19 antibody cocktail reduces viral load and alleviates symptoms
- What makes a great launch leader and launch team?
Latest intelligence
- Covid-19 redefines rules of customer engagement
- Oli Hudson, Content Director at Wilmington Healthcare, explores how the pandemic has changed pharma’s relationship with HCPs...
- Ongoing Virtual Communication between MSLs and Physicians: a Customer Story
- Learn how one of our clients used the Impetus InSite Platform to connect their MSLs with regional groups of physicians....
- The concordance conundrum: understanding the complexities of behaviour change
- Understanding behaviour change looks at the six fundamental steps required to change human behaviour and discusses why HCPs need to start here if concordance is to be improved....
Quick links
Infographics
